Home › Funds › LOS ANGELES CAPITAL MANAGEMENT LLC › HALO

LOS ANGELES CAPITAL MANAGEMENT LLC position in HALO

HALOZYME THERAPEUTICS INC · Health Care

LOS ANGELES CAPITAL MANAGEMENT LLC reported holding 1,578,537 shares of HALO (HALOZYME THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$174.3M, representing 0.60% of its reported portfolio and ranking #29 among its reported holdings. LOS ANGELES CAPITAL MANAGEMENT LLC has disclosed HALO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.58M sh
Reported value held$174.27M
Portfolio Weight0.60%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How LOS ANGELES CAPITAL MANAGEMENT LLC's HALO position evolved

LOS ANGELES CAPITAL MANAGEMENT LLC first disclosed a stake in HALO in Q3 2023 at 101,297 shares (US$3.9M). The position peaked in Q3 2026 at 1,578,537 shares, worth US$174.3M. Across 13 filings, LOS ANGELES CAPITAL MANAGEMENT LLC increased the stake 6 time(s), trimmed it 5 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 1,578,537 shares valued at US$174.3M — a reduction of -359,498 shares quarter over quarter.. Notable position changes include a 952% increase in Q2 2025 (shares rose 41% over the following quarter), a 37% trim in Q1 2026 (shares rose 21% over the following quarter), a 181% increase in Q2 2026 (shares rose 41% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 101.30K $3.87M New
Q4 2023 103.28K $3.82M Add
Q1 2024 121.00K $4.92M Add
Q2 2024 116.27K $6.09M Reduce
Q3 2024 110.63K $6.33M Reduce
Q4 2024 92.47K $4.42M Reduce
Q1 2025 92.58K $5.91M Hold
Q2 2025 973.67K $50.65M Add
Q3 2025 1.08M $79.29M Add
Q4 2025 1.10M $70.83M Add
Q1 2026 689.91K $44.59M Reduce
Q2 2026 1.94M $151.69M Add
Q3 2026 1.58M $174.27M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About HALO and 13F data

HALO (HALOZYME THERAPEUTICS INC) is a Health Care company. 44 other funds we track also report a position in HALO — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$251.9M), SNYDER CAPITAL MANAGEMENT L P (US$187.5M), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (US$178.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding HALO

All HALO fund holders →

FAQ

How long has LOS ANGELES CAPITAL MANAGEMENT LLC held HALO?

LOS ANGELES CAPITAL MANAGEMENT LLC has disclosed HALO holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is LOS ANGELES CAPITAL MANAGEMENT LLC's current position in HALO?

As of Q3 2026, LOS ANGELES CAPITAL MANAGEMENT LLC holds 1.58M shares of HALO (HALOZYME THERAPEUTICS INC), valued at $174.27M, representing 0.60% of its reported portfolio and ranking #29.

Has LOS ANGELES CAPITAL MANAGEMENT LLC been buying or selling HALO?

In the latest 13F filing (Q3 2026), LOS ANGELES CAPITAL MANAGEMENT LLC reduced its position in HALO. The position peaked in Q3 2026 at 1.58M shares.

Which other funds hold HALO?

Other major institutional holders of HALO include CONGRESS ASSET MANAGEMENT CO, SNYDER CAPITAL MANAGEMENT L P, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.